Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells

Siliciano, Janet D, Kajdas, Joleen, Finzi, Diana, Quinn, Thomas C, Chadwick, Karen, Margolick, Joseph B, Kovacs, Colin, Gange, Stephen J +1 more·2003·Nature Medicine
DOI 10.1038/nm880

Cited by (1,001)

Items 701–800 of 1,001

  1. Cancer immunotherapy of patients with HIV infection
    María González‐Cao, Javier Martínez‐Picado, Niki Karachaliou, Rafael Rosell, Andreas Meyerhans · 2018 · Clinical & Translational Oncology
  2. Novel Histone Deacetylase Inhibitors and HIV-1 Latency-Reversing Agents Identified by Large-Scale Virtual Screening
    Donya Naz Divsalar, Conrad Veranso Simoben, Cole Schonhofer, Khumoekae Richard, Wolfgang Sippl, Fidele Ntie‐Kang, Ian Tietjen · 2020 · Frontiers in Pharmacology
  3. Study of Marine Natural Products Including Resorcyclic Acid Lactones from Humicola fuscoatra That Reactivate Latent HIV-1 Expression in an in Vitro Model of Central Memory CD4+ T Cells
    Eric J. Mejia, Steven T. Loveridge, George J. Stepan, Angela Tsai, G.S. Jones, Tiffany L. Barnes, Kimberly N. White, Marija Drašković, Karen Tenney, Manuel Tsiang et al. · 2014 · Journal of Natural Products
  4. Gene-Based Immunotherapy for Human Immunodeficiency Virus Infection and Acquired Immunodeficiency Syndrome
    Boro Dropulić, Carl H. June · 2006 · Human Gene Therapy
  5. Advances in asthma, allergy and immunology series 2004: basic and clinical immunology.
    J. Chinen, W. Shearer · 2004 · Journal of Allergy and Clinical Immunology
  6. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
    María Salgado, Cristina Gálvez, Monique Nijhuis, Mi Kwon, Erwing Fabian Cardozo Ojeda, Jon Badiola, Matthew J. Gorman, Laura E. P. Huyveneers, Víctor Urrea, Alessandra Bandera et al. · 2024 · The Lancet HIV
  7. Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease
    Alton S. Barbehenn, Lei Shi, Junzhe Shao, Rebecca Hoh, Heather M. Hartig, Vivian Pae, Sannidhi Sarvadhavabhatla, Maria Sophia Donaire, Caroline H. Sheikhzadeh, Jeffrey M. Milush et al. · 2024 · Nature Communications
  8. Can HIV-1-Specific ADCC Assist the Clearance of Reactivated Latently Infected Cells?
    Wen Shi Lee, Matthew Sidney Parsons, Stephen John Kent, Marit Lichtfuss · 2015 · Frontiers in Immunology
  9. An “Escape Clock” for Estimating the Turnover of SIV DNA in Resting CD4+ T Cells
    Jeanette C. Reece, Janka Petravic, Mehala Balamurali, Liyen Loh, Shayarana L. Gooneratne, Robert De Rose, Stephen John Kent, Miles P. Davenport · 2012 · PLoS Pathogens
  10. Can HIV be cured with stem cell therapy?
    Steven G. Deeks, J M McCune · 2010 · Nature Biotechnology
  11. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response
    Wen Peng, Zhongsi Hong, Xi Chen, Hongbo Gao, Zhuanglin Dai, Jiacong Zhao, Wen Liu, Dan Li, Kai Deng · 2020 · Antimicrobial Agents and Chemotherapy
  12. HIV persistence in lymph nodes
    Riddhima Banga, Olivia Muñoz, Matthieu Perreau · 2021 · Current Opinion in HIV and AIDS
  13. Antiretroviral therapy duration and immunometabolic state determine efficacy of ex vivo dendritic cell-based treatment restoring functional HIV-specific CD8+ T cells in people living with HIV
    Marta Calvet‐Mirabent, Ildefonso Sánchez‐Cerrillo, Noa Beatriz Martin-Cofreces, Pedro Martínez‐Fleta, Hortensia de la Fuente, Ilya Tsukalov, Cristina Delgado‐Arévalo, María José Calzada, Ignacio de los Santos, Jesús Sanz et al. · 2022 · EBioMedicine
  14. Animal models for studies of HIV-1 brain reservoirs
    Emiko M. Waight, Chen Zhang, Saumi Mathews, Bhavesh D. Kevadiya, K. C. Kent Lloyd, Howard Eliot Gendelman, Santhi Gorantla, Larisa Y Poluektova, Prasanta Kumar Dash · 2022 · Journal of Leukocyte Biology
  15. Antiretroviral therapy reveals triphasic decay of intact SIV genomes and persistence of ancestral variants
    Emily J. Fray, Fengting Wu, Francesco Roberto Simonetti, Carolin Zitzmann, Narmada Sambaturu, Carmen Molina-Parı́s, Alexandra M. Bender, Po-Ting Liu, John D. Ventura, Roger W. Wiseman et al. · 2023 · Cell Host & Microbe
  16. Wogonin inhibits latent HIV-1 reactivation by downregulating histone crotonylation
    Haitao Zhang, Jinfeng Cai, Chunna Li, Lisi Deng, Hongqiong Zhu, Ting Huang, Jiacong Zhao, Jiasheng Zhou, Kai Deng, Zhongsi Hong et al. · 2023 · Phytomedicine
  17. Humanized Mice for Studies of HIV-1 Persistence and Elimination
    Chen Zhang, Lubaba A. Zaman, Larisa Y. Poluektova, Santhi Gorantla, Howard Eliot Gendelman, Prasanta Kumar Dash · 2023 · Pathogens
  18. Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection
    Eric S. Rosenberg, Marie Davidian, Harvey Thomas Banks · 2007 · Drug and Alcohol Dependence
  19. Valproic acid: a potential role in treating latent HIV infection
    Jean‐Pierre Routy · 2005 · The Lancet
  20. Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection
    Kaitlin Rainwater‐Lovett, Carrie Ziemniak, Douglas C. Watson, Katherine Luzuriaga, George Kelly Siberry, Ann M. Petru, YaHui Chen, Priyanka Uprety, Margaret M. McManus, Ya‐Chi Ho et al. · 2017 · PLoS ONE
  21. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents
    Janka Petravic, Thomas A. Rasmussen, Sharon R. Lewin, Stephen John Kent, Miles P. Davenport · 2017 · Journal of Virology
  22. Probabilistic control of HIV latency and transactivation by the Tat gene circuit
    Youfang Cao, Xue Lei, Ruy Miguel Ribeiro, Alan S. Perelson, Jie Liang · 2018 · Proceedings of the National Academy of Sciences
  23. Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking
    Insiya Z. Mukadam, Jatin Machhi, Jonathan Herskovitz, Mahmudul Hasan, Maxim D. Oleynikov, Wilson R. Blomberg, Denis A. Svechkarev, Aaron M. Mohs, You Zhou, Prasanta Kumar Dash et al. · 2019 · Biomaterials
  24. The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy
    J H Li, Jing Ma, W Kang, C F Wang, F Bai, Keke Zhao, N Yao, Q Liu, BL Dang, BW Wang et al. · 2020 · HIV Medicine
  25. In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
    Ignasi Esteban, Carmen Pastor-Quiñones, Lorena Usero, Montserrat Plana, Felipe García, Lorna Leal · 2021 · Viruses
  26. Updates on CRISPR-based gene editing in HIV-1/AIDS therapy
    Zhihao Zhang, Wei Hou, Shuliang Chen · 2022 · Virologica Sinica
  27. Isolation, Synthesis, and Structure–Activity Relationship Study on Daphnane and Tigliane Diterpenes as HIV Latency-Reversing Agents
    Ahmed H. El‐Desoky, Keisuke Eguchi, Naoki Kishimoto, Toshifumi Asano, Hikaru Kato, Yuki Hitora, Shunsuke Kotani, Teruya Nakamura, Soken Tsuchiya, Teppei Kawahara et al. · 2022 · Journal of Medicinal Chemistry
  28. The Effect of Treatment-Associated Mutations on HIV Replication and Transmission Cycles
    Madison M. Johnson, Carson Everest Jones, Daniel N. Clark · 2022 · Viruses
  29. Endothelial Cell Stimulation Overcomes Restriction and Promotes Productive and Latent HIV-1 Infection of Resting CD4 + T Cells
    Anding Shen, Jacob J. Baker, Geoffrey L. Scott, Yelena P. Davis, Yen-Yi Ho, Robert F. Siliciano · 2013 · Journal of Virology
  30. Histone deacetylase inhibitor Scriptaid reactivates latent HIV-1 promoter by inducing histone modification in in vitro latency cell lines
    Zhu · 2010 · International Journal of Molecular Medicine
  31. CD161 + CD4 + T Cells Harbor Clonally Expanded Replication-Competent HIV-1 in Antiretroviral Therapy-Suppressed Individuals
    Xiaomin Li, Zhaoli Liu, Qijuan Li, Ronglin Hu, Lu Zhao, Yanyan Yang, Jiacong Zhao, Zhuoqiong Huang, Hongbo Gao, Linghua Li et al. · 2019 · mBio
  32. Predictors of SIV recrudescence following antiretroviral treatment interruption
    Mykola Pinkevych, Christine M. Fennessey, Deborah Cromer, Carolyn Reid, Charles M. Trubey, Jeffrey D. Lifson, Brandon F. Keele, Miles P. Davenport · 2019 · eLife
  33. Extremely low viral reservoir in treated chronically HIV-1-infected individuals
    Cristina Gálvez, Víctor Urrea, Judith Dalmau, Montse Jiménez, Bonaventura Clotet, Valérie Monceaux, Nicolas Huot, Lorna Leal, Victoria González, María González‐Cao et al. · 2020 · EBioMedicine
  34. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)
    Chloe M. Orkin, Justin Stebbing, Mark Richard Nelson, Mark Bower, Margaret A. Johnson, Sundhiya Mandalia, Rachael Jones, Graeme J Moyle, Martin Fisher, Brian Gazzard · 2004 · Journal of Antimicrobial Chemotherapy
  35. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV
    Mohamed Abou‐El‐Enein, Gerhard Bauer, Petra Reinke, Matthias Renner, Christian K. Schneider · 2014 · Trends in Molecular Medicine
  36. Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial
    Erwann P. Loret, Albert Darque, Élisabeth Jouve, Elvenn A. Loret, Corinne Nicolino‐Brunet, Sophie Morange, Elisabeth Castanier, Josiane Casanova, Christine Caloustian, Charléric Bornet et al. · 2016 · Retrovirology
  37. Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era
    Koollawat Chupradit, Sutpirat Moonmuang, Sawitree Nangola, Kuntida Kitidee, Umpa Yasamut, Marylène Mougel, Chatchai Tayapiwatana · 2017 · Viruses
  38. In Vitro and In Vivo Models of HIV Latency
    James B. Whitney, Richard Brad Jones · 2018 · Advances in experimental medicine and biology
  39. Elevated Numbers of HIV-Specific Poly-Functional CD8+ T Cells With Stem Cell-Like and Follicular Homing Phenotypes in HIV-Exposed Seronegative Individuals
    Sivasankaran Munusamy Ponnan, Kannan Thiruvengadam, Sujitha Kathirvel, Janani Shankar, Akshaya Rajaraman, Manikannan Mathaiyan, Thongadi Ramesh Dinesha, Selvamuthu Poongulali, Shanmugam Saravanan, Kailapuri Gangatharan Murugavel et al. · 2021 · Frontiers in Immunology
  40. Shocking HIV-1 with immunomodulatory latency reversing agents
    Anna Kula, Anthony Rodari, Gilles Darcis, Carine M. Van Lint · 2021 · Seminars in Immunology
  41. Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy
    Alexander O. Pasternak, Jelmer Vroom, Neeltje A. Kootstra, Ferdinand W.N.M. Wit, Marijn de Bruin, Davide De Francesco, Margreet E. Bakker, Caroline Anne Sabin, Alan Winston, Jan M. Prins et al. · 2021 · eLife
  42. Mapping the interplay between NK cells and HIV: therapeutic implications
    Renee R. Anderko, Robbie B. Mailliard · 2023 · Journal of Leukocyte Biology
  43. Ex Vivo Response to Histone Deacetylase (HDAC) Inhibitors of the HIV Long Terminal Repeat (LTR) Derived from HIV-Infected Patients on Antiretroviral Therapy
    Hao Kim Lu, Lachlan R. Gray, Fiona Wightman, Paula C. Ellenberg, Gabriela Khoury, Wan‐Jung Cheng, Talia M. Mota, Steve L Wesselingh, Paul R. Gorry, Paul U. Cameron et al. · 2014 · PLoS ONE
  44. Valproic acid and HIV-1 latency: beyond the sound bite
    Stephen M. Smith · 2005 · Retrovirology
  45. Within-Host Virus Models with Periodic Antiviral Therapy
    Patrick De Leenheer · 2008 · Bulletin of Mathematical Biology
  46. Markers of the HIV-1 reservoir
    Timothée Bruel, Olivier Schwartz · 2018 · Current Opinion in HIV and AIDS
  47. Host Restriction Factors and Human Immunodeficiency Virus (HIV-1): A Dynamic Interplay Involving All Phases of the Viral Life Cycle
    Vanessa D’Urbano, Elisa De Crignis, Maria Carla Re · 2018 · Current HIV Research
  48. Lack of Evidence for Protease Evolution in HIV‐1–Infected Patients after 2 Years of Successful Highly Active Antiretroviral Therapy
    Mariona Parera, Ángela Ibáñez, Bonaventura Clotet, Miguel Ángel Martı́nez · 2004 · The Journal of Infectious Diseases
  49. Persistent HIV-1 transcription during ART: time to reassess its significance?
    Céline Fombellida-Lopez, Ben Berkhout, Gilles Darcis, Alexander O. Pasternak · 2024 · Current Opinion in HIV and AIDS
  50. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells
    Hao Yin, Yuhao Zhang, Xin Zhou, Huanzhang Zhu · 2010 · Molecular Biology Reports
  51. Fingolimod inhibits multiple stages of the HIV-1 life cycle
    Rachel Samantha Resop, Rémi Fromentin, Daniel Newman, Hawley Rigsby, Larisa Dubrovsky, Michael Bukrinsky, Nicolas Chomont, Alberto Bosque · 2020 · PLoS Pathogens
  52. SMAC Mimetics as Therapeutic Agents in HIV Infection
    Bengisu Molyer, Ashok Kumar, Jonathan Benjamin Angel · 2021 · Frontiers in Immunology
  53. Therapeutic roles of CAR T cells in infectious diseases: Clinical lessons learnt from cancer
    Mahsa Mohammadi, Maryam Akhoundi, Sara Malih, Ali Mohammadi, Mohsen Sheykhhasan · 2022 · Reviews in Medical Virology
  54. Proviral location affects cognate peptide–induced virus production and immune recognition of HIV-1–infected T cell clones
    Filippo Dragoni, Abena K. Kwaa, Caroline C. Traut, Rebecca T. Veenhuis, Bezawit A. Woldemeskel, Angelica Camilo-Contreras, Hayley E. Raymond, Arbor G. Dykema, Eileen P. Scully, Amanda M. Rosecrans et al. · 2023 · Journal of Clinical Investigation
  55. Hit-and-Run Stimulation: a Novel Concept To Reactivate Latent HIV-1 Infection without Cytokine Gene Induction
    Frank Wolschendorf, Alexandra Emilie Duverger, Jennifer Jones, Frederic H. Wagner, Jason Huff, William H. Benjamin, Michael S. Saag, Michael Niederweis, Olaf Kutsch · 2010 · Journal of Virology
  56. Development of Methods for Coordinate Measurement of Total Cell-Associated and Integrated Human Immunodeficiency Virus Type 1 (HIV-1) DNA Forms in Routine Clinical Samples: Levels Are Not Associated with Clinical Parameters, but Low Levels of Integrated HIV-1 DNA May Be Prognostic for Continued Successful Therapy
    Jillian M. Carr, Kelly M. Cheney, Carl Coolen, A. Davis, David Shaw, W. Ferguson, Gustavo Adolfo Lemos Chang, Geoff Stuart Higgins, Christopher J. Burrell, Peizhen Li · 2007 · Journal of Clinical Microbiology
  57. Differentiating Immune Cell Targets in Gut-Associated Lymphoid Tissue for HIV Cure
    Shahzada Khan, Sushama Telwatte, Martin Trapečar, Steven A. Yukl, Shomyseh Sanjabi · 2017 · AIDS Research and Human Retroviruses
  58. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques
    David Palesch, Steven E. Bosinger, Maud Mavigner, James M. Billingsley, Cameron Mattingly, Diane G. Carnathan, Mirko Paiardini, Ann Chahroudi, Thomas H. Vanderford, Guido Silvestri · 2018 · Journal of Virology
  59. Pathways towards human immunodeficiency virus elimination
    Prasanta Kumar Dash, Bhavesh D. Kevadiya, Hang Su, Mary G. Banoub, Howard Eliot Gendelman · 2020 · EBioMedicine
  60. Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages
    Kelly T. Hughes, Güray Aktürk, Sacha Gnjatic, Benjamin K. Chen, Mary E. Klotman, Maria Blasi · 2020 · AIDS
  61. Present status of human HIV vaccine development
    Sandra A. Calarota, David B. Weiner · 2003 · AIDS
  62. Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.
    Maria Carla Re, Francesca Vitone, Isabella Bon, Pasqua Schiavone, Davide Gibellini · 2006 · PubMed
  63. Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection
    Kavidha Reddy, Guinevere Q. Lee, Nicole Reddy, Tatenda JB Chikowore, Kathy J. Baisley, Krista L. Dong, Bruce D. Walker, Xu G. Yu, Mathias D. Lichterfeld, Thumbi Ndung’u · 2024 · eLife
  64. Monocyte to macrophage differentiation and changes in cellular redox homeostasis promote cell type-specific HIV latency reactivation
    Alexandra Blanco, Robert A. Coronado, Neha Arun, Kelly Ma, Roy D. Dar, Collin Kieffer · 2024 · Proceedings of the National Academy of Sciences
  65. Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions
    Antonios Mouzakis, Vasileios Petrakis, Eleni Tryfonopoulou, Maria I. Panopoulou, Periklis Panagopoulos, Katerina Chlichlia · 2025 · Current Issues in Molecular Biology
  66. Strategies to target HIV-1 in the central nervous system
    Lachlan R. Gray, Bruce James Brew, Melissa J. Churchill · 2016 · Current Opinion in HIV and AIDS
  67. Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal
    Adam M. Spivak, Racheal A. Nell, Mark E. Petersen, Laura J. Martins, Paul R. Sebahar, Ryan Looper, Vicente Planelles · 2018 · Antimicrobial Agents and Chemotherapy
  68. HIV-1 Persistence in Children during Suppressive ART
    Mary Grace Katusiime, Gert Uves van Zyl, Mark Fredric Cotton, Mary F. Kearney · 2021 · Viruses
  69. TCR-mimic bispecific antibodies to target the HIV-1 reservoir
    Srona Sengupta, Nathan L. Board, Fengting Wu, Milica Moskovljevic, Jacqueline Douglass, Josephine Zhang, Bruce B. Reinhold, Jonathan S. Duke‐Cohan, Jeanna Yu, Madison C. Reed et al. · 2022 · Proceedings of the National Academy of Sciences
  70. Intragenic proviral elements support transcription of defective HIV-1 proviruses
    Jeffrey Kuniholm, Elise M.R. Armstrong, Brandy Bernabe, Carolyn Coote, Anna Berenson, Samantha D. Drinan, Alex J. Olson, Xianbao He, Nina Lin, Juan I. Fuxman Bass et al. · 2021 · PLoS Pathogens
  71. HIV Latency in Myeloid Cells: Challenges for a Cure
    Alisha Chitrakar, Marta Sanz, Sanjay B. Maggirwar, Natalia Soriano-Sarabia · 2022 · Pathogens
  72. Forging a Functional Cure for HIV: Transcription Regulators and Inhibitors
    Sonia Mediouni, Shuang Lyu, Susan M. Schader, Susana T. Valente · 2022 · Viruses
  73. Development of a highly sensitive and specific intact proviral DNA assay for HIV-1 subtype B and C
    Ninée VEJ Buchholtz, Marieke M. Nühn, T. C. M. de Jong, T. A. T. Stienstra, Kavidha Reddy, Thumbi Ndung’u, Zaza M. Ndhlovu, Katie Fisher, Sarah Palmer, Annemarie M. J. Wensing et al. · 2024 · Virology Journal
  74. Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses
    Nesrina Imami, Samantha J. Westrop, Nathali Grageda, Anna Herasimtschuk · 2013 · Frontiers in Immunology
  75. Modeling the Timing of Antilatency Drug Administration during HIV Treatment
    Janka Petravic, Alexey Martyushev, Jeanette C. Reece, Stephen John Kent, Miles P. Davenport · 2014 · Journal of Virology
  76. Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection
    Lillian Seu, Steffanie Sabbaj, Alexandra Emilie Duverger, Frederic Wagner, Joshua Charles Anderson, Elizabeth Davies, Frank Wolschendorf, Christopher Douglas Willey, Michael S. Saag, Paul Goepfert et al. · 2015 · Journal of Virology
  77. Estimating Frequencies of Minority Nevirapine-Resistant Strains in Chronically HIV-1-Infected Individuals Naive to Nevirapine by Using Stochastic Simulations and a Mathematical Model
    Saikrishna Gadhamsetty, Narendra M. Dixit · 2010 · Journal of Virology
  78. Impact of Chromatin on HIV Replication
    Luis M. Agosto, Matthew Gagné, Andrew J. Henderson · 2015 · Genes
  79. Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers
    Benjamin B. Policicchio, Cuiling Xu, Egidio Brocca‐Cofano, Kevin D. Raehtz, Tianyu He, Dongzhu Ma, Hui Joyce Li, Ranjit Sivanandham, George Sebastian Haret-Richter, Tammy Dunsmore et al. · 2016 · PLoS Pathogens
  80. Single-molecule techniques to quantify and genetically characterise persistent HIV
    Xiao Qian Wang, Sarah Palmer · 2018 · Retrovirology
  81. Disrupting the Code: Epigenetic Dysregulation of Lymphocyte Function during Infectious Disease and Lymphoma Development
    Andrea Di Pietro, Kim L. Good‐Jacobson · 2018 · The Journal of Immunology
  82. Quantification of HIV DNA Using Droplet Digital PCR Techniques
    Elizabeth M. Anderson, Frank M. Maldarelli · 2018 · Current Protocols in Microbiology
  83. PD-1 Expression in HIV-Specific CD8+ T cells Before Antiretroviral Therapy Is Associated With HIV Persistence
    Yanina Ghiglione, César Trifone, Jimena Salido, Ajantha Rhodes, María Julia Ruiz, María L. Polo, Horacio Salomón, Natalia Laufer, Omar Gustavo Sued, Sharon R. Lewin et al. · 2018 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  84. Innate and Adaptive Factors Regulating Human Immunodeficiency Virus Type 1 Genomic Activation
    Sonia Shah, Michael R. Nonnemacher, Vanessa Pirrone, Brian L. Wigdahl · 2010 · Journal of Neuroimmune Pharmacology
  85. Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs
    Mark A. Brockman, Richard Brad Jones, Zabrina L. Brumme · 2015 · Frontiers in Immunology
  86. Cell and gene therapy strategies to eradicate HIV reservoirs
    Chelsea J. Spragg, Harshana S. De Silva Feelixge, Keith R. Jerome · 2016 · Current Opinion in HIV and AIDS
  87. Circulating CXCR5-Expressing CD8+ T-Cells Are Major Producers of IL-21 and Associate With Limited HIV Replication
    Federico Perdomo-Celis, Natalia A. Taborda, Marı́a Teresa Rugeles · 2018 · JAIDS Journal of Acquired Immune Deficiency Syndromes
  88. Seeing Is Believing: Nuclear Imaging of HIV Persistence
    Timothy J. Henrich, Priscilla Y. Hsue, Henry F. VanBrocklin · 2019 · Frontiers in Immunology
  89. HIV-1 Genomes Are Enriched in Memory CD4 + T-Cells with Short Half-Lives
    Vincent Morcilla, Charline Bacchus, Katie Fisher, Bethany A. Horsburgh, Bonnie M. Hiener, Xiao Qian Wang, Timothy E. Schlub, Mark D. Fitch, Rebecca Hoh, Frederick M. Hecht et al. · 2021 · mBio
  90. Four days a week or less on appropriate anti‐HIV drug combinations provided long‐term optimal maintenance in 94 patients: the ICCARRE project
    Jacques Leibowitch, Dominique Mathez, Pierre de Truchis, Damien Ledu, Jean Claude Melchior, Guislaine Carcelain, Jacques Izopet, Christian Perronne, John R. David · 2015 · The FASEB Journal
  91. Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART
    Nadejda Beliakova‐Bethell, Marjan Hezareh, Joseph K. Wong, Matthew C. Strain, Mary K. Lewinski, Douglas D. Richman, Celsa A. Spina · 2017 · Virology
  92. Inefficient HIV-1 trans Infection of CD4 + T Cells by Macrophages from HIV-1 Nonprogressors Is Associated with Altered Membrane Cholesterol and DC-SIGN
    Diana C. DeLucia, Charles R. Rinaldo, Giovanna Rappocciolo · 2018 · Journal of Virology
  93. Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART
    John K. Bui, Joshua C. Cyktor, Elizabeth Fyne, Shalyn C. Campellone, Stephen W. Mason, John W. Mellors · 2019 · PLoS ONE
  94. Dasatinib protects humanized mice from acute HIV-1 infection
    María Salgado, Javier Martínez‐Picado, Cristina Gálvez, Sara Rodríguez-Mora, Belén Rivaya, Víctor Urrea, Elena Mateos, José Alcamı́, Mayte Coiras · 2019 · Biochemical Pharmacology
  95. Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features
    Yannic C. Bartsch, Carolin Loos, Evan D. Rossignol, Jesse M. Fajnzylber, Dansu Yuan, Anchalee Avihingsanon, Sasiwimol Ubolyam, Thidarat Jupimai, Bernard J. Hirschel, Jintanat Ananworanich et al. · 2021 · mBio
  96. Optimisation of a TALE nuclease targeting the HIV co-receptor CCR5 for clinical application
    Lea Isabell Schwarze, Dawid Głów, Tanja Sonntag, Almut Uhde, Boris Fehse · 2021 · Gene Therapy
  97. Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
    Sean E Collins, Philip Grant, Robert W. Shafer · 2015 · Drugs
  98. Finding a Cure for Human Immunodeficiency Virus-1 Infection
    Joel N. Blankson, Janet D'Angelo Siliciano, Robert F. Siliciano · 2014 · Infectious Disease Clinics of North America
  99. Management of HIV infection in treatment-naive patients: A review of the most current recommendations
    Sarita D. Boyd · 2011 · American Journal of Health-System Pharmacy
  100. Impact of Antiretroviral Therapy Duration on HIV-1 Infection of T Cells within Anatomic Sites
    Eunok Lee, Susanne von Stockenström, Vincent Morcilla, Lina Odevall, Bonnie M. Hiener, Wei Shao, Wendy Hartogensis, Peter Bacchetti, Jeffrey M. Milush, Teri J. Liegler et al. · 2019 · Journal of Virology